Genetic KCa3.1-deficiency produces locomotor hyperactivity and alterations in cerebral monoamine levels
about
Glutamate-system defects behind psychiatric manifestations in a familial hemiplegic migraine type 2 disease-mutation mouse model.Novel phenolic inhibitors of small/intermediate-conductance Ca²⁺-activated K⁺ channels, KCa3.1 and KCa2.3Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia.Genetic Ablation of Soluble TNF Does Not Affect Lesion Size and Functional Recovery after Moderate Spinal Cord Injury in Mice.Down-regulation of KCa2.3 channels causes erectile dysfunction in miceCentral but not systemic administration of XPro1595 is therapeutic following moderate spinal cord injury in miceIFN-γ differentially modulates memory-related processes under basal and chronic stressor conditions.A novel pan-negative-gating modulator of KCa2/3 channels, fluoro-di-benzoate, RA-2, inhibits endothelium-derived hyperpolarization-type relaxation in coronary artery and produces bradycardia in vivo.The Ca²⁺-activated K⁺ channel KCa3.1 as a potential new target for the prevention of allograft vasculopathy.High expression of KCa3.1 in patients with clear cell renal carcinoma predicts high metastatic risk and poor survival.Modulation of K(Ca)3.1 channels by eicosanoids, omega-3 fatty acids, and molecular determinantsGenetic deficit of KCa 3.1 channels protects against pulmonary circulatory collapse induced by TRPV4 channel activation.Cell therapy centered on IL-1Ra is neuroprotective in experimental stroke.Conditional ablation of myeloid TNF increases lesion volume after experimental stroke in mice, possibly via altered ERK1/2 signaling.Activation of KCa3.1 by SKA-31 induces arteriolar dilatation and lowers blood pressure in normo- and hypertensive connexin40-deficient mice.Endothelial small-conductance and intermediate-conductance KCa channels: an update on their pharmacology and usefulness as cardiovascular targets.KCa 3.1-a microglial target ready for drug repurposing?Cerebrospinal fluid levels of catecholamines and its metabolites in Parkinson's disease: effect of l-DOPA treatment and changes in levodopa-induced dyskinesia.The calcium-activated potassium channel KCa3.1 is an important modulator of hepatic injury.Vascular Reactivity Profile of Novel KCa 3.1-Selective Positive-Gating Modulators in the Coronary Vascular Bed.Genetic ablation of soluble tumor necrosis factor with preservation of membrane tumor necrosis factor is associated with neuroprotection after focal cerebral ischemia.Dopamine plasma clearance is increased in piglets compared to neonates during continuous dopamine infusion.Mitochondrial DNA Double-Strand Breaks in Oligodendrocytes Cause Demyelination, Axonal Injury, and CNS Inflammation.Senicapoc: Repurposing a Drug to Target Microglia KCa3.1 in Stroke.Long-term sensitization training in Aplysia decreases the excitability of a decision-making neuron through a sodium-dependent mechanism.Established amyloid-β pathology is unaffected by chronic treatment with the selective serotonin reuptake inhibitor paroxetine.
P2860
Q27340464-0F3A5E4C-563F-4982-A042-5AE1BE63426AQ28488052-4E7AB7EE-273A-4544-A2DE-0F315E88F780Q30610169-F1C905ED-0BC4-431E-B27C-EF6AA711613FQ30833318-7DDB46A3-CD5B-4703-87B2-2AE0A0DFEE1CQ33812566-C445E3ED-8BFC-4C6E-A04C-A8DABE56C4B8Q34250544-7458E5E7-A008-4A30-B7EA-3A511A0B3A7AQ34547416-822745DE-9806-449F-A3B2-0E29FCA25116Q34946861-43E74D57-49E2-4ED9-91B4-8A2D56ED83CFQ35060404-D30127A2-27C0-49F1-80A4-4F0307BF0603Q35304761-251DA34B-C0DD-4AA9-80BE-29702058C591Q35395940-6CB0B409-24D9-49E7-B5C8-FA75A0079F2DQ36036232-E0FFB86C-21C9-4B60-AEFB-F8D43107431CQ36809420-57078D34-6155-4D7D-8492-1D13BA36C1D8Q37072728-121498F7-99DC-4910-B616-1AE23CFA4211Q37327372-1866D672-281A-488F-AB0A-1D3FC504B6A6Q38056312-E2F1CBB1-F246-4AF7-87DF-8EDC79C7064FQ38819263-F77BBFA3-AF93-469C-B65A-169A45507934Q38937893-BE4994AF-4217-4096-9A32-DC6CBDABD2ABQ39647330-07C090AB-4492-4CCD-92DB-6B93A7D70464Q40048355-8A7CEDC7-678C-47AD-9129-6BC0BB62A86FQ41022804-5EE04731-AADB-4C9B-95FB-B415A8A205E7Q47300197-E5FE703C-72C4-4BEE-8D22-A47FC8FB8785Q47633073-BC6B8207-06B7-4362-AAD0-D3C0FE33DD33Q48236109-5948D5D3-E545-4BB7-9039-B6FBB85A28A6Q55100421-FED236D9-8BA1-4D73-8C2B-420259FC217CQ55399027-3A945B7C-029A-4595-9B08-B75F62C50833
P2860
Genetic KCa3.1-deficiency produces locomotor hyperactivity and alterations in cerebral monoamine levels
description
2012 nî lūn-bûn
@nan
2012 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Genetic KCa3.1-deficiency prod ...... s in cerebral monoamine levels
@ast
Genetic KCa3.1-deficiency prod ...... s in cerebral monoamine levels
@en
Genetic KCa3.1-deficiency prod ...... s in cerebral monoamine levels
@nl
type
label
Genetic KCa3.1-deficiency prod ...... s in cerebral monoamine levels
@ast
Genetic KCa3.1-deficiency prod ...... s in cerebral monoamine levels
@en
Genetic KCa3.1-deficiency prod ...... s in cerebral monoamine levels
@nl
prefLabel
Genetic KCa3.1-deficiency prod ...... s in cerebral monoamine levels
@ast
Genetic KCa3.1-deficiency prod ...... s in cerebral monoamine levels
@en
Genetic KCa3.1-deficiency prod ...... s in cerebral monoamine levels
@nl
P2093
P2860
P50
P1433
P1476
Genetic KCa3.1-deficiency prod ...... s in cerebral monoamine levels
@en
P2093
Heike Wulff
Jan Bert Gramsbergen
Linda Maria Sevelsted-Møller
Mithula Sivasaravanaparan
Nicholas Ditzel
Ralf Köhler
P2860
P304
P356
10.1371/JOURNAL.PONE.0047744
P407
P577
2012-10-15T00:00:00Z